“Brodalumab in the treatment of moderate-to-severe psoriasis in patients refractory to anti-interleukin-17A therapies: Evaluation of secondary endpoints” (2021) SKIN The Journal of Cutaneous Medicine, 5(5), pp. 524–529. doi:10.25251/skin.5.5.10.